All In Biotech

Drug Trial Radar · NCT05922436

a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency

A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the Efficacy and Safety of Intravenous QLG2071 Versus Cleviprex® for Patients With Hypertensive Emergency and Sub-emergency

Last checked: Nov 20, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

378

Planned (sponsor's estimate)

Start

Jul 15, 2023

Primary completion

May 24, 2024

Study completion May 25, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the efficacy and safety of QLG2071 Versus Cleviprex® in the Treatment of Hypertensive Emergency and Sub-emergency

Conditions

  • Hypertensive Emergency

Interventions

  • QLG2071Drug

    intravenous injection

  • Cleviprex®Drug

    intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the percentage of patients who reach the target range (Systolic Blood Pressure decreased by ≥15% and ≤25% from baseline) within 30 minutes of administrationTime frame: Within 30 minutes of the initiation of the infusion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.